Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
Anti-cancer immunotherapies, particularly immune checkpoint inhibitors, have significantly advanced oncology treatments but are associated with rare, potentially severe cardiotoxicities. Despite their success, these therapies are associated with immune-related adverse events including rare but sever...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
EDP Sciences
2025-01-01
|
| Series: | Visualized Cancer Medicine |
| Subjects: | |
| Online Access: | https://vcm.edpsciences.org/articles/vcm/full_html/2025/01/vcm20240019/vcm20240019.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Anti-cancer immunotherapies, particularly immune checkpoint inhibitors, have significantly advanced oncology treatments but are associated with rare, potentially severe cardiotoxicities. Despite their success, these therapies are associated with immune-related adverse events including rare but severe immunotherapy-related cardiotoxicities. This review examines various immunotherapy types, such as immune checkpoint inhibitors, adoptive T-cell therapies, and cancer vaccines, highlighting their cardiovascular risks. Cardiotoxicities can lead to life-threatening complications, especially in high-risk patients. Early detection and prevention are crucial, with comprehensive cardiovascular assessments and routine biomarker monitoring playing a central role. With immunotherapies becoming more prevalent, this review calls for stronger evidence-based guidelines to manage and prevent these cardiovascular complications, ensuring that patients can benefit from life-saving immunotherapies without jeopardizing cardiovascular health. |
|---|---|
| ISSN: | 2740-4218 |